Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price was down 3% on Thursday . The company traded as low as $44.67 and last traded at $44.84, with a volume of 174,044 shares changing hands. The stock had previously closed at $46.25.

A number of equities analysts have recently weighed in on FPRX shares. Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $48.00 price objective on shares of Five Prime Therapeutics in a research report on Thursday, May 19th. Leerink Swann reissued a “buy” rating and issued a $45.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, July 15th. Finally, Jefferies Group set a $60.00 target price on shares of Five Prime Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $52.33.

The stock’s 50 day moving average price is $46.78 and its 200-day moving average price is $41.47. The company has a market capitalization of $1.23 billion and a PE ratio of 5.12.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The business had revenue of $9.23 million for the quarter, compared to the consensus estimate of $6.38 million. The business’s revenue for the quarter was up 46.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.45) EPS. Analysts anticipate that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current year.

In other news, Director William R. Ringo sold 500 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $50.77, for a total transaction of $25,385.00. Following the completion of the transaction, the director now owns 500 shares in the company, valued at approximately $25,385. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Peder Jensen sold 12,195 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total transaction of $603,652.50. Following the transaction, the director now owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Five Prime Therapeutics stock. RS Investment Management Co. LLC acquired a new stake in shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 511,170 shares of the company’s stock, valued at approximately $21,214,000. RS Investment Management Co. LLC owned 1.86% of Five Prime Therapeutics as of its most recent filing with the SEC.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.